OpenURL Connection Search

Select item for more details and to access through your institution.

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2.
Published in:
Hematological Oncology, 2023, v. 41, p. 849, doi. 10.1002/hon.3166_OT28
By:
- Sehn, L. H;
- Chamuleau, M.;
- Lenz, G.;
- Clausen, M. R.;
- Haioun, C.;
- Izutsu, K.;
- Davies, A.;
- Zhu, J.;
- Oki, T.;
- Szafer‐Glusman, E.;
- Conlon, R.;
- Chiou, H.;
- Ipe, D.;
- Elliot, B.;
- Wu, J.;
- Salles, G.
Publication type:
Article
Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibody.
Published in:
Hematological Oncology, 2023, v. 41, p. 326, doi. 10.1002/hon.3164_232
By:
- Soong, D.;
- Thieblemont, C.;
- Karavitis, J.;
- Hess, B.;
- Caimi, P.;
- Feldman, T.;
- Hutchings, M.;
- Sureda, A.;
- Szafer‐Glusman, E.;
- Sacchi, M.;
- Jure‐Kunkel, M.;
- Adya, N.;
- Chiu, C.
Publication type:
Article
FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 238, doi. 10.1002/hon.3163_155
By:
- Ghia, P.;
- Allan, J. N.;
- Siddiqi, T.;
- Wierda, W. G.;
- Tam, C. S.;
- Moreno, C.;
- Tedeschi, A.;
- Szafer‐Glusman, E.;
- Zhou, C.;
- Abbazio, C.;
- Dean, J. P.;
- Szoke, A.;
- Barr, P. M.
Publication type:
Article
PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.78_2881
By:
- Chiu, C. W.;
- Hiemstra, I. H.;
- ten Hagen, W.;
- Snijdewint‐Nkairi, R.;
- de Jong, B.;
- Garrido Castro, P.;
- Kweekel, C.;
- Oliveri, R. S.;
- Elliot, B.;
- Wielgos‐Bonvallet, M.;
- Szafer‐Glusman, E.;
- Schuurhuis, D.;
- Blaedel, J.;
- Ahmadi, T.;
- Breij, E.;
- Sasser, A.K.;
- Jure‐Kunkel, M.
Publication type:
Article
CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.32_2879
By:
- Tam, C. S. L;
- Allan, J. N;
- Siddiqi, T;
- Kipps, T. J;
- Jacobs, R;
- Opat, S;
- Barr, P. M;
- Tedeschi, A;
- Trentin, L;
- Bannerji, R;
- Jackson, S;
- Kuss, B;
- Moreno, C;
- Szafer‐Glusman, E;
- Russell, K;
- Zhou, C;
- Ninomoto, J;
- Dean, J. P;
- Ghia, P;
- Wierda, W. G
Publication type:
Article
IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 135, doi. 10.1002/hon.95_2629
By:
- Morschhauser, F.;
- Flinn, I.W.;
- Gasiorowski, R.;
- Illés, Á.;
- Feugier, P.;
- Greil, R.;
- Johnson, N.A.;
- Larouche, J.;
- Lugtenburg, P.J.;
- Patti, C.;
- Salles, G.;
- Trněný, M.;
- Vos, S.;
- Mir, F.;
- Kornacker, M.;
- Punnoose, E.A.;
- Samineni, D.;
- Szafer‐Glusman, E.;
- Petrich, A.;
- Sinha, A.
Publication type:
Article
REAL‐WORLD PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION AMONG DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH FIRST‐LINE R‐CHOP.
Published in:
Hematological Oncology, 2019, v. 37, p. 351, doi. 10.1002/hon.14_2631
By:
- Downer, M.K.;
- Chaudhary, N.;
- Szafer‐Glusman, E.;
- Breuleux, M.;
- Hsi, E.D.;
- Biondo, J.M.;
- Bazeos, A.;
- Jiang, Y.
Publication type:
Article
IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 135, doi. 10.1002/hon.95_2629
By:
- Morschhauser, F.;
- Flinn, I.W.;
- Gasiorowski, R.;
- Illés, Á.;
- Feugier, P.;
- Greil, R.;
- Johnson, N.A.;
- Larouche, J.;
- Lugtenburg, P.J.;
- Patti, C.;
- Salles, G.;
- Trněný, M.;
- Vos, S.;
- Mir, F.;
- Kornacker, M.;
- Punnoose, E.A.;
- Samineni, D.;
- Szafer‐Glusman, E.;
- Petrich, A.;
- Sinha, A.
Publication type:
Article
REAL‐WORLD PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION AMONG DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH FIRST‐LINE R‐CHOP.
Published in:
Hematological Oncology, 2019, v. 37, p. 351, doi. 10.1002/hon.14_2631
By:
- Downer, M.K.;
- Chaudhary, N.;
- Szafer‐Glusman, E.;
- Breuleux, M.;
- Hsi, E.D.;
- Biondo, J.M.;
- Bazeos, A.;
- Jiang, Y.
Publication type:
Article
EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 96, doi. 10.1002/hon.2437_85
By:
- Huet, S.;
- Szafer ‐ Glusman, E.;
- Xerri, L.;
- Bolen, C.;
- Punnoose, E.;
- Tonon, L.;
- Tilly, H.;
- Brice, P.;
- Feugier, P.;
- Tesson, B.;
- Viari, A.;
- Venstrom, J.M.;
- Salles, G.
Publication type:
Article

Found: 10